HSBC Upgrades Gilead Sciences to Hold, Announces $69 Price Target
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt upgrades Gilead Sciences (GILD) from Reduce to Hold and sets a $69 price target, indicating a neutral outlook on the stock.

April 24, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HSBC upgrades Gilead Sciences to Hold and sets a $69 price target, suggesting a neutral stance on the stock's short-term movement.
The upgrade from Reduce to Hold by HSBC reflects a change in the bank's outlook on Gilead Sciences, moving from a negative to a neutral stance. The announcement of a $69 price target indicates HSBC's expectation that GILD will not experience significant price movement in the short term. This analysis is based on HSBC's assessment and could influence investor sentiment, potentially stabilizing GILD's stock price around the current levels or moving it towards the target price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90